Torkom Garabedian in Andover, Massachusetts

Medical School: Sorry, his university is not listed
Graduation Year: 2011
The Primary Medical Specialty for Torkom Garabedian is listed as: Internal Medicine
Approximate Years of Experience: 13
PAC (PECOS ID)#: 9032407341
NPI #: 1063852127
NPI Created On: 07/03/2013
NPI Last Updated Listed as: 10/26/2017
Primary Taxonomy Code: 207R00000X
License Number:
265716
Listed Gender: Male

---

Forms of insurance accepted by include, but are not limited to:

• Harvard Pilgrim Health Care Inc.
• Medicare

They are listed as accepting new patients.

---

Services and Procedures include:

1. Blood glucose (sugar) level after receiving dose of glucose
2. Hemoglobin a1c level
3. Vaccine for influenza for injection into muscle
4. Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older
5. Routine ekg using at least 12 leads including interpretation and report
6. Established patient office or other outpatient visit, typically 10 minutes
7. Established patient office or other outpatient visit, typically 15 minutes
8. Established patient office or other outpatient, visit typically 25 minutes
9. Established patient office or other outpatient, visit typically 40 minutes
10. Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes
11. Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes
12. Physician telephone patient service, 11-20 minutes of medical discussion
13. Physician telephone patient service, 21-30 minutes of medical discussion
14. Administration of influenza virus vaccine
15. Administration of pneumococcal vaccine
16. Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

They took part in the Medicare Physician Quality Reporting System (PQRS).

They took part in the Million Hearts Initiative, which was deigned to improve cardiac outcomes.